HX 100

Drug Profile

HX 100

Latest Information Update: 13 Aug 2015

Price : $50

At a glance

  • Originator Hydra Biosciences
  • Class Antiallergics; Antiasthmatics; Small molecules
  • Mechanism of Action TRPA1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Allergic asthma; Neuropathic pain

Most Recent Events

  • 05 Aug 2015 Phase-I clinical trials in Neuropathic pain (In volunteers) in Canada (PO)
  • 05 Aug 2015 Phase-I clinical trials in Allergic asthma (In volunteers) in Canada (PO)
  • 14 Apr 2015 Health Canada approves clinical trial application for HX 100 in Neuropathic pain and Allergic asthma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top